BioInvent receives €2 million milestone payment from Daiichi Sankyo for licensed n-CoDeR® antibody progressing into Phase I clinical trial
Lund, Sweden – 29 February 2016 – BioInvent International (BINV) today announced that it will receive a €2 million milestone payment under the collaboration with Daiichi Sankyo pertaining to the progression of an anti-FGFR4 antibody into a Phase I clinical trial in the EU.
BioInvent receives €2 million milestone payment from Daiichi Sankyo for licensed n-CoDeR® antibody progressing into Phase I clinical trial
Lund, Sweden – 29 February 2016 – BioInvent International (BINV) today announced that it will receive a €2 million milestone payment under the collaboration with Daiichi Sankyo pertaining to the progression of an anti-FGFR4 antibody into a Phase I clinical trial in the EU.
http://www.bioinvent.se/media-centre/press-releases/release/?ReleaseID=0343D46385679286